Novartis Completes Its Business Portfolio Restructuring, Divesting Gerber for US$5.5 Billion to Nestle
April 12, 2007 01:52 ET | Novartis
* Divestiture program completed with Novartis business portfolio now entirely focused on healthcare * Joseph Jimenez named new CEO of Consumer Health division BASEL, Switzerland, April 12,...
Novartis Announces Initiative to Improve Access to State-of-the-Art Anti-Malarial Treatment Coartem
September 29, 2006 01:10 ET | Novartis
-- Malaria strikes 300 million to 500 million people every year, the biggest killer of children in Africa -- every 30 seconds a child in Africa dies of this disease -- Average cost per...
Novartis Awarded Up to USD220 Million by U.S. Department of Health and Human Services for Development of Cell Culture-Derived Influenza Vaccine
May 04, 2006 10:41 ET | Novartis
-- Novartis Vaccines leadership in new cell-culture based influenza vaccine development acknowledged -- Importance of new technologies recognized by U.S. government to provide quick and...
Novartis Delivers Strong Start to 2006 in First Quarter with Excellent Sales and Earnings Growth Performance
April 24, 2006 02:48 ET | Novartis
BASEL, Switzerland, April 24, 2006 (PRIMEZONE) -- -- Group first quarter net sales up 13% in USD (+17% in local currencies) based on strong underlying sales expansion in all ...
New Drug Application for Rasilez, an Innovative Oral Renin Inhibitor to Treat High Blood Pressure, Accepted for U.S. Regulatory Review
April 20, 2006 01:44 ET | Novartis
BASEL, Switzerland, April 20, 2006 (PRIMEZONE) -- -- Renin inhibitors would be the first new class of high blood pressure medicines available in more than 10 years -- U.S. Submission...
Novartis Delivers Strong Performance with Record Results in 2005
January 19, 2006 01:30 ET | Novartis
-- Group full-year net sales up 14% in USD (+13% lc) thanks to dynamic expansion of Novartis Pharmaceuticals and Sandoz, the latter supported by acquisitions -- Pharmaceuticals...
Novartis Announces Leadership of New Vaccines and Diagnostics Business
November 03, 2005 01:58 ET | Novartis
BASEL, Switzerland, Nov. 3, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS) announced today that it has designated Dr. Joerg Reinhardt, currently Global Head of Pharma Development, to become CEO of a new...
Novartis Announces Agreement to Acquire Remaining Stake in Chiron
October 31, 2005 04:45 ET | Novartis
-- Acquisition provides Novartis with attractive growth platforms in the dynamic vaccines market and in a rapidly growing molecular diagnostic business -- Biopharmaceutical activities...
Novartis Delivers Strong Growth in First Nine Months of 2005 on Track to Achieve Full-Year Sales and Earnings Objectives
October 18, 2005 01:44 ET | Novartis
-- Group nine-month net sales rise 14% in USD (+12% lc), thanks to strong underlying growth and market share gains in all divisions -- Pharmaceuticals growth of 11% (+9% lc) for first nine...
Novartis: FTY720 Phase II 12-month Data Show Sustained Benefits and Good Tolerability in Patients with Relapsing Multiple Sclerosis
October 01, 2005 03:11 ET | Novartis
BASEL, Switzerland, Oct. 1, 2005 (PRIMEZONE) -- Data from the extension of a Phase II study to 12 months confirm the significant effects of FTY720, a novel oral medication, for the treatment of...